Syncom Formulations FY26 Profit Hits Rs 76 Crore with Leadership Overhaul

Profit After Tax rose to Rs 76.01 crore in FY 2025-26, compared to Rs 48.87 crore in the previous year.
Total Income reached Rs 517.54 crore for the year, marking a steady increase from Rs 480.04 crore in FY 2024-25.
Reader Takeaway: Strong double-digit profit growth drives investor confidence, while the leadership transition remains a key area for execution monitoring.

What just happened

Syncom Formulations India Ltd released its 38th Annual Report, confirming a dividend payout of Rs 0.10 per share (10%). The board has scheduled the Annual General Meeting for September 30, 2026. Alongside these financial disclosures, the company confirmed a major management reshuffle following the resignations of key outgoing directors.

Why this matters

The jump in Profit Before Tax from Rs 64.66 crore to Rs 100.53 crore highlights substantial operational efficiency. The transition to a new Managing Director, Rahul Vijay Bankda, and a new CFO, Ankur Vijay Bankda, marks a generational shift in leadership for the pharmaceutical firm, which currently maintains a presence across 15+ countries and relies on a large sales force of 1,000+ medical representatives.

Management and Governance Update

Effective August 12, 2026, Rahul Vijay Bankda assumes the role of Managing Director, while Rinki Ankit Bankda joins as a Whole-time Director. Ankur Vijay Bankda has taken charge as the Chief Financial Officer. These appointments replace the outgoing leadership of Kedarmal Shankarlal Bankda and Vijay Shankarlal Bankda.

Context metrics

The company reported a strong start to the new fiscal year, with Q1 FY26-27 consolidated income growing 8% to Rs 133.36 crore and Profit Before Tax surging 59% to Rs 32.25 crore.

What to track next

Investors should look for the outcome of the upcoming AGM on September 30 and monitor whether the new leadership team can sustain the current trajectory of margin expansion in competitive global pharmaceutical markets.